Author/Creator: Kim, D-W - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Kim, D-W

1. 1396PEfficacy and safety of crizotinib in previously treated patients (Pts) with ALK+ advanced non-small cell lung cancer (NSCLC) aged ≥65 years (y). (23rd October 2018)

Authors:: Moro-Sibilot, D; Ahn, M-J; Halmos, B; Kim, D-W; Riely, G J; Shaw, A T; Yang, P-C; Lanzalone, S; Polli, A; Wilner, K D; De Castro Carpeño, J
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. 1397PLong-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:: Crinò, L; Ahn, M-J; Han, J-Y; Liu, X; Ou, S-H I; Shaw, A T; Yang, P-C; Shi, Y-K; Lanzalone, S; Polli, A; Wilner, K D; Kim, D-W
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. 1443PReal world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset. (23rd October 2018)

Authors:: Kang, J H; Cho, B C; Kim, D-W; Park, K; Lee, J-S; Yoo, S S; Lee, S Y; Kim, C H; Jang, S H; Kim, Y-C; Yoon, H-K; Kim, S-W
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. 1674PSafety of belotecan as second-line treatment for recurrent small cell lung cancer: A phase IIb randomized multicenter study. (23rd October 2018)

Authors:: Kang, J H; Kim, H T; Lee, K H; Kim, D-W; Kim, S-W; Kim, H R; Kim, J-H; Choi, J H; An, H J; Kim, J-S; Jang, J S; Kim, B-S
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). (24th November 2019)

Authors:: Lee, D H; Subbiah, V; Gainor, J F; Taylor, M H; Zhu, V W; Doebele, R C; Lopes, G; Baik, C; Garralda, E; Gadgeel, S M; Kim, D-W; Turner, C D; Palmer, M; Miller, S; Curigliano, G
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. 373PMolecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001). (24th November 2019)

Authors:: Tan, A C; Loong, H; Ho, G F; Seet, A; Chiam, B; Cheah, D Q; Tan, G S; Lim, K H; Yang, J C-H; Mok, T S K; Kim, D-W; Tan, D S W
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. 414PDPhase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (23rd October 2018)

Authors:: Cho, B C; Perets, R; Bar, J; Ahn, M-J; Kim, D-W; Yoh, K; Nagrial, A; Spigel, D R; Lee, D H; Gutierrez, M; Kotasek, D; Siddiqi, S; Chain, A; Butts, B D; Zhang, Y; Li, X; Cyrus, J; Tse, A; Altura, R A; Rasco, D
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. 466OASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test. (25th November 2018)

Authors:: Freitas, H C; Park, K; Kim, D-W; Tiseo, M; Hochmair, M J; Chang, G-C; Shi, Y-K; Moran, T; Chen, Y; Laskin, J; Solomon, B; Miranda, M; Rigas, J; Cheema, P K; Kim, S-W
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

9. 477OTepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. (24th November 2019)

Authors:: Park, K; Zhou, J; Kim, D-W; Ahmad, A R; Soo, R A; Bruns, R; Straub, J; Johne, A; Scheele, J; Yang, J C-H; Wu, Y-L
Journal:: Annals of oncology
Issue:: Volume 30(2019)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

10. 517PA real-world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis. (25th November 2018)

Authors:: Lee, J-S; Cho, B C; Kim, D-W; Park, K; Kang, J H; Yoo, S S; Lee, S Y; Kim, C H; Jang, S H; Kim, Y C; Yoon, H-K; Kim, S-W
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 9
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗